Hikma takes Amarin's 'skinny label' fight to the Supreme Court
Hikma Pharmaceuticals is asking the US Supreme Court to review a generic drug labeling ruling that it says will “effectively vitiate” a common practice that helps bring more low-cost medications to market. The
Hikma Pharmaceuticals is asking the US Supreme Court to review a generic drug labeling ruling that it says will “effectively vitiate” a common practice that helps bring more low-cost medications to market.
The
